

AMENDMENT

In the Claims

Please amend the following claims:

- B1
1. (currently amended) A method of treatment of an existing human papillomavirus (HPV) infection comprising: administering a composition therapeutic vaccine comprising (a) PV VLPs selected from the group consisting of PV L1 VLPs or (b) PV L1 VLPs and PV L1/L2 VLPs to a patient suffering from the PV infection characterized in that said therapeutic vaccine excludes PV E protein.
 2. (previously presented) The method of treatment according to Claim 1, wherein the PV infection is characterised by the presence of epithelial lesions.
 3. (previously presented) The method of treatment according to Claim 2, wherein the epithelial lesions are selected from the group consisting of palmar warts, planter warts, ano-genital warts, flat and planar warts of the skin and muscosal surfaces, CIN, equine sarcoid and replicating or vegetative PV infection.
 4. (previously presented) The method of treatment according to Claim 3, wherein the epithelial lesions are genital warts caused by HPV 6, 11, 34, 39, 41, 42, 43, 44, 51, 52, 53, 54, or 55.
 - B2
5. (currently amended) The method of treatment according to Claim 4, wherein the genital warts are caused by HPV 6 ~~or~~ and HPV 11.
 6. (withdrawn) A method of producing a PV VLP comprising: (a) cloning one or more PV VLP genes into a vector and (b) expressing the one or more PV VLP genes in an eukaryotic cell transduced by the vector.
 - B3
7. (withdrawn) The method according to Claims 1-5, further comprising: cloning the PV L1 or PV L2 gene into a vector and expressing the PV L1 or PV L2 gene in a host cell.
 8. (withdrawn) The method according to Claim 6, wherein the one or more PV VLP

genes comprise (i) a PV L1 VLP gene or (ii) a PV L1 VLP gene and a PV L2 VLP gene, wherein the vector is an expression vector, wherein the host cell is a cell from a permissive cell line.

B3
w
9. (withdrawn) The method according to Claim 6, wherein the permissive cell line is a Sf9 insect cell line and the expression vector is a baculovirus expression vector.

10. (withdrawn) The method according to Claim 8, wherein the permissive cell line is a procaryotic cell line.

B4
11. (currently amended) The method according to Claim 1, wherein the concentration of PV L1 VLPs ~~or PV L1 VLPs and PV L2 VLPs~~ administered to the patient is 0.5-20 µg.

12. (previously presented) The method according to Claim 11, wherein the concentration is 1-10 µg.

B5
13. (currently amended) The method according to Claim ~~11 or 12~~ 1, wherein ~~the composition is administered~~ dosages of PV VLPs are given 3-6 times over a period of 8-16 weeks.

14. (currently amended) The method according to Claim ~~11~~ 1, wherein ~~the composition is administered~~ dosages of PV VLPs are given 3-6 times over a period of 2-4 weeks.

15. (withdrawn) A method of immunization against HPV11 infection comprising administering HPV6 VLPs to a patient.

B6
16. (withdrawn) The method according to Claim 15, wherein the HPV6 VLPs are HPV6b VLPs.

17. (withdrawn) The method according to Claim 15, wherein the concentration of the HPV6 VLPs are 0.5-20 µg.

18. (withdrawn) The method according to Claim 17, wherein the concentration of the HPV6 VLPs are 1-10 µg.
19. (withdrawn) The method according to Claim 17, wherein the HPV6 VLPs are administered 3-6 times over a period of 8-16 weeks.
20. (withdrawn) The method according to Claim 17, wherein the HPV6 VLPs are administered 3-6 times over a period of 24 weeks.
21. (withdrawn) A method of immunization against HPV6 infections comprising administering HPV11 VLPs to a patient.
22. (withdrawn) The method according to Claim 21, wherein the concentration of the HPV11 VLPs is 0.5-20 µg.
23. (withdrawn) The method according to Claim 22, wherein the concentration of the HPV11 VLPs is 1-10 µg.
24. (withdrawn) The method of according to Claim 22 or 23, wherein the HPV11 VLPs are administered 3-6 times over a period of 8-16 weeks.
25. (withdrawn) Method according to Claim 22 or 23, wherein the HPV11 VLPs are administered 3-6 times over a period of 2-4 weeks.
26. (withdrawn) A method of treatment of an existing papillomavirus infection comprising administering papillomavirus VLPs without adjuvant to a patient suffering from the papillomavirus infection.
- 27-31. (canceled).
32. (currently amended) The method according to Claim 1, wherein the ~~composition lack~~ an VLPs excludes adjuvant.

33. (new) The method of treatment as claimed in Claim 1, wherein the VLPs are produced by cloning the PV L1 gene into a suitable vector and expressing the corresponding conformational coding sequence for L1 in an eukaryotic cell transduced by the vector.